How to Buy Catalyst Pharmaceuticals Stock
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
Catalyst Pharmaceuticals stock last closed at $20.40, up 1.9% from the previous day, and has decreased 0.15% in one year. It has overperformed other stocks in the Biotechnology industry by 0.46 percentage points. Catalyst Pharmaceuticals stock is currently +6.53% from its 52-week low of $19.15, and -23.25% from its 52-week high of $26.58.
As of Sep 18, 2025, there are 122.39M shares of CPRX outstanding. The market value of CPRX is $2.50B. In the last 24 hours, 1.4M CPRX shares were traded.
How to Buy Catalyst Pharmaceuticals Stock
Not sure how to invest in Catalyst Pharmaceuticals stock? Here's how.
- Decide where to buy Catalyst Pharmaceuticals stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Catalyst Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Select your payment method and add your information.
- Research Catalyst Pharmaceuticals stock: The Catalyst Pharmaceuticals ticker symbol is CPRX. Is Catalyst Pharmaceuticals stock a good investment? Should you buy shares of CPRX? How do CPRX's underlying business fundamentals look? Do top analysts think Catalyst Pharmaceuticals is a good buy? Why has CPRX's stock price moved recently? (Hint: Our stock research website can help you evaluate if CPRX is a good stock to buy).
- Execute your CPRX buy order: Decide if you will purchase CPRX shares at the current market price or use a limit order to purchase CPRX shares at a given price.
- Keep tabs on your investment in CPRX: Create a watchlist to important notifications about your position in Catalyst Pharmaceuticals shares.
Step 1: Decide where to buy Catalyst Pharmaceuticals stock
You need an online brokerage account to access the NASDAQ market and buy CPRX shares.
Our preferred brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global financial markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy CPRX stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start a new trading account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've opened your account on a investment app, you can securely and quickly fund your account:
Watch the video below if you need help depositing money into your new brokerage account.
Step 4: Research Catalyst Pharmaceuticals stock
After you have identified the best place to buy Catalyst Pharmaceuticals stock, it's crucial to evaluate their stock before you invest, so you can understand the risk and upside.
Catalyst Pharmaceuticals stock at a glance
CPRX Due Diligence Score
WallStreetZen was created to help everyday investors perform more in-depth fundamental analysis.
You can see all of the due diligence checks on CPRX's stock page.
How is CPRX stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge CPRX's fair value.
Using relative valuations metrics:
- CPRX may be undervalued based on its P/E ratio of 11.79x, relative to Biotechnology industry P/E ratio of -101.52x
- CPRX could be undervalued based on its P/B ratio of 2.92x, relative to Biotechnology industry P/B ratio of 4.84x
- CPRX could be undervalued based on its PEG ratio of 0.88x
You can do additional valuation research on CPRX's stock here.
CPRX Financial Summary
Positive Financial Indicators:
- There are more short-term assets than short-term liabilities on the CPRX balance sheet.
- There are more short-term assets than long-term liabilities on the CPRX balance sheet.
- CPRX profit margin has gone up from 15.7% to 37.4% in the past year.
- CPRX's operating cash flow of $275.09M allows it to safely service it's debt of $2.57M.
- Total CPRX debt is lower than 5 years ago, relative to shareholder equity.
- CPRX has a low debt to equity ratio of 0.14.
- CPRX earnings of $271.97M is not sufficient to cover its interest payments.
You can dive deeper into what analysts are saying on the Catalyst Pharmaceuticals stock forecast page.
CPRX Technicals
CPRX Revenue
Last year, CPRX earnings were $208.67M. During the past five year, CPRX's earnings have gone up by 34.03% per year. This was faster than the Biotechnology industry average of 9.11%.
Last year, CPRX revenue was $558.50M. Over the last 5 year, CPRX's revenue has gone up by 36.06% per year. This was slower than the Biotechnology industry average of 67.22%.
Find out more about CPRX's earnings and revenue performance here.
What are CPRX insiders up to?
In the last 12 months, executives and large shareholders at CPRX have bought more shares than they have sold.
Brian Elsbernd, Chief ComplianceLegal Officer of CPRX, was the latest CPRX insider to buy. They bought $251,944.00 worth of CPRX shares on Sep 8, 2025.
Learn more about who owns CPRX shares here.
Can I get consistent income from CPRX stock?
No, Catalyst Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about CPRX
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your CPRX buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open Trade button and your broker will execute your order.
If you require additional help with buying stocks on eToro, click the how to video below:
Step 6: Keep tabs on your investment in CPRX
Now that you own some shares in CPRX, you'll want to keep up with your new stock purchase.
Put CPRX on a watchlist to track the most important metrics related to your CPRX stock.
CPRX Feed
How to Buy Stock in Catalyst Pharmaceuticals
To reiterate, here are the 6 steps you need to take to buy Catalyst Pharmaceuticals stock right now:
- Decide where to buy Catalyst Pharmaceuticals stock
- Create your brokerage account
- Deposit money your investment account
- Research Catalyst Pharmaceuticals stock
- Execute your CPRX buy order
- Keep tabs on your investment in CPRX
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Catalyst Pharmaceuticals, hit the button below to create your watchlist.
More Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.